--- title: "Oragenics | 10-Q: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/285768695.md" datetime: "2026-05-08T20:04:11.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285768695.md) - [en](https://longbridge.com/en/news/285768695.md) - [zh-HK](https://longbridge.com/zh-HK/news/285768695.md) --- # Oragenics | 10-Q: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.51. EBIT: As of FY2026 Q1, the actual value is USD -2.293 M. Oragenics, Inc. operates in a single reportable segment, focused on the development of ONP-002 for mild traumatic brain injury (concussion). #### Revenue Oragenics, Inc. did not generate any revenue for the three months ended March 31, 2026, or 2025. #### Operating Expenses Research and development (R&D) expenses increased by 88.9% to $645,470 for the three months ended March 31, 2026, from $341,542 in the same period of 2025, primarily due to higher external professional and consulting costs related to the ONP-002 concussion program. General and administrative (G&A) expenses decreased by 4.4% to $1,610,457 for the three months ended March 31, 2026, compared to $1,684,685 in the prior-year period, mainly due to lower patent-related expenses and reduced headcount, partially offset by increased legal, professional, and investor relations fees. Total operating expenses were $2,255,927 for the three months ended March 31, 2026, up from $2,026,227 for the same period in 2025. #### Loss from Operations Loss from operations was - $2,255,927 for the three months ended March 31, 2026, compared to - $2,026,227 for the same period in 2025. #### Other Income (Expense) Total other income, net, was $32,059 for the three months ended March 31, 2026, a significant change from total other expense of - $190,766 in the same period of 2025. This shift was driven by a decrease in interest expense (from - $199,127 in 2025 to - $3,727 in 2026) and an increase in interest income (from $10,203 in 2025 to $40,876 in 2026), partially offset by higher foreign currency exchange net losses (from - $1,842 in 2025 to - $5,090 in 2026). #### Net Loss Net loss for the three months ended March 31, 2026, was - $2,201,243, which was an improvement from - $2,216,993 for the same period in 2025. #### Cash Flow Net cash used in operating activities was - $2,200,644 for the three months ended March 31, 2026, compared to - $2,112,090 for the same period in 2025. Net cash provided by investing activities was $4,000,000 for the three months ended March 31, 2026, primarily from the sale of short-term investments, with no comparable activity in 2025. Net cash used in financing activities was - $92,004 for the three months ended March 31, 2026, a decrease from $4,668,328 provided by financing activities in the prior-year period. Cash and cash equivalents at the end of the period were $6,107,078 as of March 31, 2026, compared to $3,421,078 as of March 31, 2025. #### Balance Sheet Highlights As of March 31, 2026, cash and cash equivalents were $6,107,078, down from $4,399,726 as of December 31, 2025. Total current assets were $7,489,636 at March 31, 2026, decreasing from $10,067,764 at December 31, 2025. Total liabilities decreased to $1,307,878 at March 31, 2026, from $1,786,359 at December 31, 2025. Total stockholders’ equity was $6,181,758 at March 31, 2026, down from $8,281,405 at December 31, 2025. The accumulated deficit was - $228,829,902 as of March 31, 2026. #### Operational Metrics and Strategic Summary Oragenics, Inc. is advancing ONP-002, a neurosteroid for mild traumatic brain injury, through clinical trials, having initiated Phase IIa clinical trials in Australia in Q1 2026. The company also entered into a Letter of Intent on May 7, 2026, to license CardioDialysis™, a blood purification technology, from Sigyn Therapeutics, Inc. for the treatment of Traumatic Brain Injury and other chronic neurodegenerative diseases. #### Outlook and Guidance Oragenics, Inc. anticipates R&D expenses to increase in future periods due to the advancement of the ONP-002 program, including initiating a Phase IIa clinical trial in Australia, conducting IND-enabling activities for a U.S. Phase IIb trial, and scaling manufacturing. General and administrative expenses are expected to remain relatively consistent, with potential increases from legal, regulatory, public company compliance, and investor relations activities. The company believes its current working capital of $6.1 million will fund planned operations through December 31, 2026, but additional capital will be required to complete planned clinical trials and commercialization efforts. ### Related Stocks - [OGEN.US](https://longbridge.com/en/quote/OGEN.US.md) ## Related News & Research - [Oragenics advances ONP-002 Phase IIa in Australia, $6.1M cash and LOI for CNS device](https://longbridge.com/en/news/286915159.md) - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md) - [Hafnia’s Q1 2026 Financial Results Presentation to Be Held on 27 May 2026 | HAFN Stock News](https://longbridge.com/en/news/287014236.md)